在充血性心力衰竭中,右心室血管相互作用. 低频阻抗的重要性
W G Kussmaul1, J A Altschuler, W H Matthai
1Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia.
Circulation
|September 1, 1993
概括
尼托普鲁西德通过改变肺动脉血动力学来改善心力衰竭中的心脏输出. 低剂量可以通过阻抗变化减少冲击体积,而高剂量可以改善流量并减少功率需求.
科学领域:
- 心脏病学 心脏病学
- 血液动力学 血液动力学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管扩张剂对于治疗充血性心力衰竭至关重要.
- 它们对脉动性右心室液压负荷的影响很大.
研究的目的:
- 为了研究尼特罗普鲁西德对肺动脉 (PA) 脉动性血液动力学的影响,在患有严重结血性心力衰竭的患者中.
- 为了将血液动力学变化与心脏输出和中风体积的变化相关联.
主要方法:
- 15名患者使用高保真度压力传感器和流速探针进行心脏导管治疗.
- 在分级的化注入过程中持续记录PA压力和流量.
- 使用富里埃变换来推导PA阻抗,液压功率和波反射指数.
主要成果:
- 较高的尼托普鲁塞德剂量显著改善了心脏输出,降低了PA压力,电阻,阻抗和波反射.
- 较低剂量通过低频阻抗变化改变了PA血液动力学,有时会降低中风体积.
- 第一个阻力的变化与低剂量的中风体积变化相关.
结论:
- 尼特普鲁西德通过肺血管扩张影响心力衰竭中的心室血管相互作用.
- 了解脉动性血液动力学特性对于理解酸对心脏输出的影响至关重要.
- 在较高的剂量下,化通过改善前向流量和减少液压功率需求而带来好处.
更多相关视频
相关概念视频
Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.


